Does anlotinib improve progression-free survival and reduce adverse events compared to pazopanib in patients with metastatic alveolar soft part sarcoma?
Anlotinib may provide superior progression-free survival and a better safety profile compared to pazopanib in patients with metastatic alveolar soft part sarcoma.
Compared to pazopanib, anlotinib yielded longer PFS and lower incidence of AEs in ASPS patients. Drug dosage reduction was more frequently encountered with the former agent and affected the disease control.
Liu et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: